Mitochondrial function in cardiac hypertrophy

International Journal of Cardiology

Volumn 167, Issue 4, 2013, Pages 1118-1125

  Zhou, Lu Yu ^a   Liu, Jin Ping ^a   Wang, Kun ^a   Gao, Jie ^a   Ding, Su Ling ^a   Jiao, Jian Qin ^a   Li, Pei Feng ^a  

^a INSTITUTE OF ZOOLOGY   (China)

Author keywords

ATP; Cardiac hypertrophy; Mitochondria; Reactive oxygen species; Therapeutics

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CANDESARTAN; CARIPORIDE; CARNITINE; CARVEDILOL; CREATINE; CYTOCHROME C OXIDASE; DICHLOROACETIC ACID; DILTIAZEM; EMD 87580; GLYCOGEN SYNTHASE KINASE 3BETA; LOSARTAN; MITOCHONDRIAL DNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; RANOLAZINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SODIUM PROTON EXCHANGE PROTEIN 1; TRANSCRIPTION FACTOR NRF1; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; BIOGENESIS; CALCIUM HOMEOSTASIS; DRUG TARGETING; ENERGY METABOLISM; EXERCISE; FATTY ACID OXIDATION; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATION REDUCTION STATE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ATP; CARDIAC HYPERTROPHY; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; THERAPEUTICS;

ANIMALS; CARDIOMEGALY; HUMANS; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84881477008     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.082     Document Type: Review

References (131)

1. F.H. Epstein, J.J. Hunter, and K.R. Chien Signaling pathways for cardiac hypertrophy and failure N Engl J Med 12 1999 1276 1283
2. J.R. McMullen, and G.L. Jennings Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure Clin Exp Pharmacol Physiol 34 2007 255 262
3. J. Wikman-Coffelt, W.W. Parmley, and D.T. Mason The cardiac hypertrophy process. Analyses of factors determining pathological vs physiological development Circ Res 45 1979 697 707
4. R. Albin, R.T. Dowell, R. Zak, and M. Rabinowitz Synthesis and degradation of mitochondrial components in hypertrophied rat heart Biochem J 136 1973 629 637
5. D.J. Pagliarini, S.E. Calvo, and B. Chang A mitochondrial protein compendium elucidates complex I disease biology Cell 134 2008 112 123
6. S. DiMauro, and E.A. Schon Mitochondrial respiratory-chain diseases N Engl J Med 348 2003 2656 2668
7. J.A. Petros, A.K. Baumann, and E. Ruiz-Pesini mtDNA mutations increase tumorigenicity in prostate cancer Proceedings of the National Academy of Sciences of the United States of America 102 2005 719 724
8. D.C. Wallace A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine Annu Rev Genet 39 2005 359 407
9. D.C. Wallace Mitochondrial diseases in man and mouse Science 283 1999 1482 1488
10. M.T. Lin, and M.F. Beal Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 443 2006 787 795
11. H. Esterbauer, H. Oberkofler, F. Krempler, and W. Patsch Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression Genomics 62 1999 98 102
12. P. Puigserver, Z. Wu, C.W. Park, R. Graves, M. Wright, and B.M. Spiegelman A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis Cell 92 1998 829 839
13. I. Irrcher, P.J. Adhihetty, T. Sheehan, A.M. Joseph, and D.A. Hood PPAR γ coactivator-1α expression during thyroid hormone- and contractile activity-induced mitochondrial adaptations Am J Physiol Cell Physiol 284 2003 C1669 C1677
14. J. St-Pierre, S. Drori, and M. Uldry Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators Cell 127 2006 397 408
15. K.A. Rasbach, and R.G. Schnellmann Signaling of mitochondrial biogenesis following oxidant injury J Biol Chem 282 2007 2355 2362
16. I. Irrcher, V. Ljubicic, and D.A. Hood Interactions between ROS and AMP kinase activity in the regulation of PGC-1α transcription in skeletal muscle cells Am J Physiol Cell Physiol 296 2009 C116 C123
17. Z. Wu, P. Puigserver, and U. Andersson Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 Cell 98 1999 115 124
18. M. Iemitsu, T. Miyauchi, and S. Maeda Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat Am J Physiol Regul Integr Comp Physiol 281 2001 R2029 R2036
19. P.A. Watson, J.E.B. Reusch, and S.A. McCune Restoration of CREB function is linked to completion and stabilization of adaptive cardiac hypertrophy in response to exercise Am J Physiol Heart Circ Physiol 293 2007 H246 H259
20. B.T. O'Neill, J. Kim, and A.R. Wende A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy Cell Metab 6 2007 294 306
21. O.J. Kemi, M.A. Høydal, and P.M. Haram Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan Cardiovasc Res 76 2007 91 99
22. J.R. McMullen, T. Shioi, and L. Zhang Phosphoinositide 3-kinase (p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy Proc Natl Acad Sci 100 2003 12355
23. T. Shioi, P.M. Kang, and P.S. Douglas The conserved phosphoinositide 3-kinase pathway determines heart size in mice EMBO J 19 2000 2537 2548
24. S.R. Stuewe, P.A. Gwirtz, N. Agarwal, and R.T. Mallet Exercise training enhances glycolytic and oxidative enzymes in canine ventricular myocardium J Mol Cell Cardiol 32 2000 903 913
25. S. Terblanche, K. Gohil, L. Packer, S. Henderson, and G. Brooks The effects of endurance training and exhaustive exercise on mitochondrial enzymes in tissues of the rat (Rattus norvegicus) Comp Biochem Physiol A Mol Integr Physiol 128 2001 889 896
26. S. Kayar, K. Conley, H. Claassen, and H. Hoppeler Capillarity and mitochondrial distribution in rat myocardium following exercise training J Exp Biol 120 1986 189 199
27. K. Asayama, K. Dobashi, H. Hayashibe, Y. Megata, and K. Kato Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat: a possible mechanism of injury to heart and skeletal muscle in hyperthyroidism Endocrinology 121 1987 2112 2118
28. M.D. Brand, and M.P. Murphy Control of electron flux through the respiratory chain in mitochondria and cells Biol Rev 62 1987 141 193
29. M. López-Torres, M.I. Romero, and G. Barja Effect of thyroid hormones on mitochondrial oxygen free radical production and DNA oxidative damage in the rat heart Mol Cell Endocrinol 168 2000 127 134
30. P. Venditti, C. Agnisola, and S. Di Meo Effect of ischemia-reperfusion on heart mitochondria from hyperthyroid rats Cardiovasc Res 56 2002 76 85
31. S.P. Bishop, and R.A. Altschuld Increased glycolytic metabolism in cardiac hypertrophy and congestive failure Am J Physiol - Legacy Content 218 1970 153 159
32. H. Taegtmeyer, and M.L. Overturf Effects of moderate hypertension on cardiac function and metabolism in the rabbit Hypertension 11 1988 416 426
33. C. Depre, G.L. Shipley, and W. Chen Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy Nat Med 4 1998 1269 1275
34. M.N. Sack, T.A. Rader, S. Park, J. Bastin, S.A. McCune, and D.P. Kelly Fatty acid oxidation enzyme gene expression is downregulated in the failing heart Circulation 94 1996 2837 2842
35. J.J. Lehman, and D.P. Kelly Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth Heart Fail Rev 7 2002 175 185
36. S. Oka, R. Alcendor, and P. Zhai PPARα-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway Cell Metab 14 2011 598 611
37. B.N. Finck, and D.P. Kelly Peroxisome proliferatorâ€? activated receptor γ coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease Circulation 115 2007 2540 2548
38. M. Sano, S.C. Wang, and M. Shirai Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure EMBO J 23 2004 3559 3569
39. S. Wang, C. Fu, and H. Wang Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy Clin Chem Lab Med 45 2007 962 967
40. J.J. Lehman, and D.P. Kelly Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart Clin Exp Pharmacol Physiol 29 2002 339 345
41. R. Ventura-Clapier, A. Garnier, and V. Veksler Transcriptional control of mitochondrial biogenesis: the central role of PGC-1 α Cardiovasc Res 79 2008 208 217
42. W. Sperl, P. Jesina, and J. Zeman Deficiency of mitochondrial ATP synthase of nuclear genetic origin Neuromuscul Disord 16 2006 821 829
43. J.M. O'Donnell, A. Fields, X. Xu, S.A.K. Chowdhury, D.L. Geenen, and J. Bi Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo Am J Physiol Heart Circ Physiol 295 2008 H2483 H2494
44. T. Doenst, G. Pytel, and A. Schrepper Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload Cardiovasc Res 86 2010 461
45. I. Luptak, J.A. Balschi, Y. Xing, T.C. Leone, D.P. Kelly, and R. Tian Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-{alpha}-null hearts can be rescued by increasing glucose transport and utilization Circulation 112 2005 2339 2346
46. D. Neglia, A. De Caterina, and P. Marraccini Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy Am J Physiol Heart Circ Physiol 293 2007 H3270 H3278
47. T. Sakurabayashi, S. Miyazaki, and Y. Yuasa L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis Circ J 72 2008 926 931
48. R. Takahashi, T. Asai, and H. Murakami Pressure overload induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation Hypertension 50 2007 497 502
49. H.C. Chiu, A. Kovacs, and R.M. Blanton Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy Circ Res 96 2005 225 233
50. T. Kato, S. Niizuma, and Y. Inuzuka Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure clinical perspective Circ Heart Fail 3 2010 420 430
51. M. Luedde, U. Fl gel, and M. Knorr Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy J Mol Med 87 2009 411 422
52. T. Tanaka, K. Sohmiya, and K. Kawamura Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? J Mol Cell Cardiol 29 1997 121 127
53. J.J. Lehman, P.M. Barger, A. Kovacs, J.E. Saffitz, D.M. Medeiros, and D.P. Kelly Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis J Clin Invest 106 2000 847 906
54. A. Garnier, D. Fortin, C. Delomenie, I. Momken, V. Veksler, and R. Ventura-Clapier Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles J Physiol 551 2003 491 501
55. 2 + and proton flux dysregulation J Mol Cell Cardiol 48 2010 663 672
56. B.H. Graham, K.G. Waymire, B. Cottrell, I.A. Trounce, G.R. MacGregor, and D.C. Wallace A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator Nat Genet 16 1997 226 234
57. M.P. Cole, L. Chaiswing, and T.D. Oberley The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity Cardiovasc Res 69 2006 186 197
58. Y. Zhao, L. Wang, and L. Chaiswing Tamoxifen protects against acute tumor necrosis factor α-induced cardiac injury via improving mitochondrial functions Free Radic Biol Med 40 2006 1234 1241
59. J.E. Baker, J. Su, and X. Fu Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and KATP channels J Mol Cell Cardiol 43 2007 437 444
60. V.P.M. van Empel, A.T. Bertrand, and R.J. van Oort EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant J Am Coll Cardiol 48 2006 824 832
61. H. Du, L. Guo, and F. Fang Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease Nat Med 14 2008 1097 1105
62. J. Liu, J. Zhou, W. An, Y. Lin, Y. Yang, and W. Zang Apocynin attenuates pressure overload-induced cardiac hypertrophy in rats by reducing levels of reactive oxygen species Can J Physiol Pharmacol 88 2010 745 752
63. S. Wenzel, C. Rohde, S. Wingerning, J. Roth, G. Kojda, and K.D. Schluter Lack of endothelial nitric oxide synthase-derived nitric oxide formation favors hypertrophy in adult ventricular cardiomyocytes Hypertension 49 2007 193 200
64. T. Hu, F. Xu, Y. Li, and J. Luo Simvastatin inhibits leptin\induced hypertrophy in cultured neonatal rat cardiomyocytes1 Acta Pharmacol Sin 27 2006 419 422
65. P. Abraham, V.K. Kolli, and S. Rabi Melatonin attenuates Methotrexate©\induced oxidative stress and renal damage in rats Cell Biochem Funct 28 2010 426 433
66. S. Kawakami, A. Matsuda, and T. Sunagawa Antioxidant, EUK-8, prevents murine dilated cardiomyopathy Circ J 73 2009 2125 2134
67. E.H. Sarsour, M. Goswami, A.L. Kalen, and P.C. Goswami MnSOD activity protects mitochondrial morphology of quiescent fibroblasts from age associated abnormalities Mitochondrion 10 2010 342 349
68. C. Du, Z. Gao, and V.A. Venkatesha Mitochondrial ROS and radiation induced transformation in mouse embryonic fibroblasts Cancer Biol Ther 8 2009 1962 1971
69. H. Nojiri, T. Shimizu, and M. Funakoshi Oxidative stress causes heart failure with impaired mitochondrial respiration J Biol Chem 281 2006 33789 33801
70. H. Misawa, K. Nakata, and J. Matsuura Conditional knockout of Mn superoxide dismutase in postnatal motor neurons reveals resistance to mitochondrial generated superoxide radicals Neurobiol Dis 23 2006 169 177
71. H. Kayabasi, D. Sit, A.E. Atay, Z. Yilmaz, A.K. Kadiroglu, and M.E. Yilmaz Parameters of oxidative stress and echocardiographic indexes in patients on dialysis therapy Ren Fail 32 2010 328 334
72. F. Qin, S. Lennon-Edwards, and S. Lancel Cardiac-specific overexpression of catalase identifies hydrogen peroxide-dependent and -independent phases of myocardial remodeling and prevents the progression to overt heart failure in Gαq-overexpressing transgenic mice Circ Heart Fail 3 2010 306 313
73. H. Bugger, M. Schwarzer, and D. Chen Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure Cardiovasc Res 85 2010 376 384
74. J. Bauersachs, and A. Schafer Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches Curr Vasc Pharmacol 2 2004 115 124
75. H. El Azzouzi, R.J. Van Oort, R. Van Der Nagel, W. Sluiter, M.W. Bergmann, and L.J. De Windt MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload Eur J Heart Fail 12 2010 4 12
76. A. Planavila and X. Palomer Atorvastatin inhibits GSK-3β phosphorylation by cardiac hypertrophic stimuli Biochim Biophys Acta Mol Cell Biol Lipids 1781 2008 26 35
77. Y.V. Postnov, S.N. Orlov, Y.Y. Budnikov, A.D. Doroschuk, and A.Y. Postnov Mitochondrial energy conversion disturbance with decrease in ATP production as a source of systemic arterial hypertension Pathophysiology 14 2007 195 204
78. K. Indira Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy Cell Biochem Funct 26 2008 346 351
79. H.L. Li, Y. Huang, and C.N. Zhang Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and-independent signal pathways Free Radic Biol Med 40 2006 1756 1775
80. J. Cai, F.F. Yi, and Z.Y. Bian Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway J Cell Mol Med 13 2009 909 925
81. +-ATPase regulation Fundam Clin Pharmacol 22 2008 615 621
82. J. Guo, Z. Gertsberg, N. Ozgen, and S.F. Steinberg p66Shc links α 1-adrenergic receptors to a reactive oxygen species-dependent Akt-Foxo3a phosphorylation pathway in cardiomyocytes Circ Res 104 2009 660 669
83. X.J. Zou, L. Yang, and S.L. Yao Propofol depresses angiotensin II-induced cardiomyocyte hypertrophy in vitro Exp Biol Med 233 2008 200 208
84. 2-induced injury on cardiac myocytes via its target gene PDCD4 J Mol Cell Cardiol 47 2009 5 14
85. E. Yoshihara, Z. Chen, Y. Matsuo, H. Masutani, and J. Yodoi Thiol redox transitions by thioredoxin and thioredoxin-binding protein-2 in cell signaling Methods Enzymol 474 2010 67 82
86. 2 + channels Circulation 119 2009 2435 2443
87. B.J. Wilkins, and J.D. Molkentin Calcium-calcineurin signaling in the regulation of cardiac hypertrophy Biochem Biophys Res Commun 322 2004 1178 1191
88. 2 +/calmodulin-dependent protein kinase II (CaMKII) in the heart Calcium Signal 2012 685 702
89. J.J. Lemasters, and E. Holmuhamedov Voltage-dependent anion channel (VDAC) as mitochondrial governator - thinking outside the box Biochim Biophys Acta 1762 2006 181 190
90. 2 + uniport Nat Cell Biol 9 2007 445 452
91. J.A. Hill Electrical remodeling in cardiac hypertrophy Trends Cardiovasc Med 13 2003 316 322
92. T.I. Peng, and M.J. Jou Oxidative stress caused by mitochondrial calcium overload Ann N Y Acad Sci 1201 2010 183 188
93. S. Javadov, and M. Karmazyn Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection Cell Physiol Biochem 20 2007 1 22
94. M. Marcil, A. Ascah, J. Matas, S. Bélanger, C.F. Deschepper, and Y. Burelle Compensated volume overload increases the vulnerability of heart mitochondria without affecting their functions in the absence of stress J Mol Cell Cardiol 41 2006 998 1009
95. J. Matas, N. Tien Sing Young, and C. Bourcier-Lucas Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy J Mol Cell Cardiol 46 2009 420 430
96. K.S. Dimmer, F. Navoni, and A. Casarin LETM1, deleted in Wolf-Hirschhorn syndrome is required for normal mitochondrial morphology and cellular viability Hum Mol Genet 17 2008 201 214
97. S. Tamai, H. Iida, and S. Yokota Characterization of the mitochondrial protein LETM1, which maintains the mitochondrial tubular shapes and interacts with the AAA-ATPase BCS1L J Cell Sci 121 2008 2588 2600
98. L. Piao, Y. Li, and S.J. Kim Association of LETM1 and MRPL36 contributes to the regulation of mitochondrial ATP production and necrotic cell death Cancer Res 69 2009 3397
99. E. Jambrina, R. Alonso, and M. Alcalde Calcium influx through receptor-operated channel induces mitochondria-triggered paraptotic cell death J Biol Chem 278 2003 14134 14145
100. Y. Kirichok, G. Krapivinsky, and D.E. Clapham The mitochondrial calcium uniporter is a highly selective ion channel Nature 427 2004 360 364
101. 2 + uptake Nature 467 2010 291 296
102. J.M. Baughman, F. Perocchi, and H.S. Girgis Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter Nature 476 2011 341 345
103. 2 + exchange Proc Natl Acad Sci 107 2010 436 441
104. P.A. Poole-Wilson, K. Swedberg, and J.G.F. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
105. F.C. Barone, R.N. Willette, A.H. Nelson, E.H. Ohlstein, D.P. Brooks, and R.W. Coatney Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction Pharmacology 80 2007 166 176
106. 2-mediated oxidative insult in H9C2 myocardial cells Biochim Biophys Acta Bioenerg 1767 2007 222 232
107. A. Kumar, S. Dogra, and A. Prakash Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against d-galactose induced senescence in mice Naunyn Schmiedebergs Arch Pharmacol 380 2009 431 441
108. P.J. Oliveira, A.P. Rolo, C.M. Palmeira, and A.J.M. Moreno Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase Cardiovasc Toxicol 1 2001 205 213
109. M. Suwa, Y. Hirota, and K. Kawamura Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: an echocardiographic study Am J Cardiol 54 1984 1047 1053
110. J. Shao, N. Iwashita, and F. Ikeda Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on β-cell function and morphology in db/db mice Biochem Biophys Res Commun 344 2006 1224 1233
111. E. de Cavanagh, J.E. Toblli, L. Ferder, B. Piotrkowski, I. Stella, and F. Inserra Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine Am J Physiol Regul Integr Comp Physiol 290 2006 R1616 R1625
112. D.J. Hausenloy, S.Y. Lim, S.G. Ong, S.M. Davidson, and D.M. Yellon Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning Cardiovasc Res 88 2010 67 74
113. N. Johnson, A. Khan, S. Virji, J.M. Ward, and M. Crompton Import and processing of heart mitochondrial cyclophilin D Eur J Biochem 263 1999 353 359
114. C.P. Connern, and A.P. Halestrap Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel Biochem J 302 1994 321 324
115. E. Palma, T. Tiepolo, and A. Angelin Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice Hum Mol Genet 18 2009 2024 2031
116. S.Y. Lim, D.J. Hausenloy, and S. Arjun Mitochondrial cyclophilin⠀? D as a potential therapeutic target for post� myocardial infarction heart failure J Cell Mol Med 15 2011 2443 2451
117. + exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action J Appl Physiol 105 2008 1706 1713
118. S. Javadov, V. Rajapurohitam, A. Kilic, A. Zeidan, A. Choi, and M. Karmazyn Anti-hypertrophic effect of NHE-1 inhibition involves GSK-3β-dependent attenuation of mitochondrial dysfunction J Mol Cell Cardiol 46 2009 998 1007
119. + exchanger isoform 1 inhibition is mediated by reduced mitogen-activated protein kinase activation secondary to improved mitochondrial integrity and decreased generation of mitochondrial-derived reactive oxygen species J Pharmacol Exp Ther 317 2006 1036 1043
120. S.K. Engle, P.F. Solter, and K.M. Credille Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor-α/γ dual agonist using natriuretic peptides and imaging Toxicol Sci 114 2010 183 192
121. W. Linz, P. Wohlfart, and M. Baader The peroxisome proliferator-activated receptor-α (PPARα) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats Acta Pharmacol Sin 30 2009 935 946
122. C.H. Chang, L.A. McNamara, and M.S. Wu A novel selective peroxisome proliferator-activator receptor-γ modulator-SPPARγM5 improves insulin sensitivity with diminished adverse cardiovascular effects Eur J Pharmacol 584 2008 192 201
123. S. Ichihara, K. Obata, and Y. Yamada Attenuation of cardiac dysfunction by a PPARα agonist is associated with down-regulation of redox-regulated transcription factors J Mol Cell Cardiol 41 2006 318 329
124. L. Cheng, G. Ding, and Q. Qin Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy Nat Med 10 2004 1245 1250
125. C. Riehle, A.R. Wende, and V.G. Zaha PGC-1β deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Novelty and significance Circ Res 109 2011 783 793
126. H.J. Choi, and C.D. Montemagno Artificial organelle: ATP synthesis from cellular mimetic polymersomes Nano Lett 5 2005 2538 2542
127. V. Reddy, S. Bhandari, and A.M.L. Seymour Myocardial function, energy provision, and carnitine deficiency in experimental uremia J Am Soc Nephrol 18 2007 84 92
128. R.B. Wambolt, G.D. Lopaschuk, R.W. Brownsey, and M.F. Allard Dichloroacetate improves postischemic function of hypertrophied rat hearts J Am Coll Cardiol 36 2000 1378 1385
129. M. Lindbom, T. Ramunddal, G. Camejo, F. Waagstein, and E. Omerovic In vivo effects of myocardial creatine depletion on left ventricular function morphology and lipid metabolism: study in a mouse model J Card Fail 14 2008 161 166
130. D. Graham, N.N. Huynh, and C.A. Hamilton Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy Hypertension 54 2009 322 328
131. S. Rastogi, V.G. Sharov, and S. Mishra Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure Am J Physiol Heart Circ Physiol 295 2008 H2149 H2155